Wednesday, 27 October 2010
Phase III study with teriflunomide as adjunct therapy with interferon beta to further explore clinical benefits in multiple sclerosis
TERACLES is the first phase III study of an oral drug as an add-on to standard therapy in relapsing multiple sclerosis.
Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta). Teriflunomide is a novel oral disease modifier developed by sanofi-aventis which is being investigated in a large Phase III clinical development program. It includes studies of teriflunomide in monotherapy for the treatment of RMS and in clinically isolated syndrome as well as adjunct therapy. Read more here.